Last update 04 Nov 2026
Servier (Beijing) Pharmaceutical R&D Co., Ltd.

Servier (Beijing) Pharmaceutical R&D Co., Ltd.

Private Company | Subsidiary Company|2001|Beijing Shi, China|
www.servier.com.cn

Overview

Tags

Neoplasms
Skin and Musculoskeletal Diseases
Other Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Hemic and Lymphatic Diseases2
Neoplasms2
Immune System Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
IDH1(Isocitrate dehydrogenase [NADP] cytoplasmic)1
BRAF x RAS1

Related

2
Drugs associated with Servier (Beijing) Pharmaceutical R&D Co., Ltd.
Ivosidenib
Target
IDH1
Mechanism
IDH1 inhibitors [+1]
Active Org.
Institut de Recherches Intern Servier [+15]
Originator Org.
Celgene Corp.Celgene Corp.
Active Indication
Myelodysplastic Syndromes [+21]
Inactive Indication
Advanced biliary tract cancer [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date20 Jul 2018
BDTX-4933
Target
BRAF x RAS
Mechanism
BRAF inhibitors [+1]
Active Org.
Institut de Recherches Internationales Servier [+3]
Originator Org.
Black Diamond Therapeutics, Inc.Black Diamond Therapeutics, Inc.
Active Indication
Acute Myeloid Leukemia with Myelodysplasia-Related Changes [+17]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Servier (Beijing) Pharmaceutical R&D Co., Ltd.
CTR20254821
/ Active, not recruitingNot Applicable
一项在健康成年参与者中评估两个生产厂生产的 Vorasidenib 40 mg片剂在空腹条件下的单中心、开放标签、随机、单剂量、两周期、两序列、交叉生物等效性研究
[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence study evaluating Vorasidenib 40 mg tablets from two different manufacturers in healthy adult participants under fasting conditions.
ChiCTR-TRC-08000290
/ CompletedPhase 4IIT
A randomised, double-blind, placebo-controlled study of almitrine bismesylate 30 mg and raubasine 10 mg in patients with vascular cognitive impairment no dementia
100 Clinical Results associated with Servier (Beijing) Pharmaceutical R&D Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Servier (Beijing) Pharmaceutical R&D Co., Ltd.
Login to view more data
100 Deals associated with Servier (Beijing) Pharmaceutical R&D Co., Ltd.
Login to view more data
100 Translational Medicine associated with Servier (Beijing) Pharmaceutical R&D Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2
1
1
Phase 3
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Ivosidenib
 ( IDH1 )		Chondrosarcoma
More
Phase 3
BDTX-4933
 ( BRAF x RAS )		Advanced cancer
More
IND Approval
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free